


Docket No: PH-7134

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Elliott Korsen
Type or print name


Signature

August 13, 2003
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: **1654**

Copeland *et al.*

Examiner: **Jeffrey E. Russel**

APPLICATION NO: **09/808,832**

FILED: **March 15, 2001**

RECEIVED

**PEPTIDASE-CLEAVABLE , TARGETED ANTINEOPLASTIC
DRUGS AND THEIR THERAPEUTIC USE**

AUG 19 2003

TECH CENTER 1600/2900

Mail Stop: AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

COMMUNICATION

This Communication is being submitted with the Amendment filed August 13, 2003 in order to record the substance of the personal interview held on July 1, 2003 with Examiner Russel.

Applicants' attorney provided the Examiner with proposed amended claims including the introduction of certain negative claim limitations in Claim 1. All of these were presented to overcome the art rejections from Paper No. 14 and found support within the Specification as filed. Certain other minor amendments were proposed to claims 4,5 and 30 to overcome the 112 rejections.


Applicants' attorney also proposed providing a new Substitute Specification to include changes to the sequence numbering used in the application. The statement of no new matter which was omitted in the response containing the prior Substitute Specification will be included with the new Substitute Specification.

No other specific matters were discussed.

The outcome of the interview was that Applicants' attorney agreed to make the

proposed changes in order to overcome the outstanding rejections. The Examiner indicated that these changes might put the application in condition for allowance.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Elliott Kersen", written over a horizontal line.

Elliott Kersen
Attorney for Applicants
Reg. No. 32,705

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-4741

Date: August 13, 2003